BS_GCQFGDTX
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 13.042049934296976
- age_years
- 6.14
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.644
- E2F_TARGETS+0.619
- MYC_TARGETS_V1+0.619
- G2M_CHECKPOINT+0.586
- PANCREAS_BETA_CELLS+0.332
- DNA_REPAIR+0.317
- UNFOLDED_PROTEIN_RESPONSE+0.271
- MITOTIC_SPINDLE+0.207
- WNT_BETA_CATENIN_SIGNALING+0.180
- SPERMATOGENESIS+0.163
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.679
- INTERFERON_GAMMA_RESPONSE-0.572
- INFLAMMATORY_RESPONSE-0.500
- NOTCH_SIGNALING-0.461
- IL2_STAT5_SIGNALING-0.455
- ALLOGRAFT_REJECTION-0.447
- IL6_JAK_STAT3_SIGNALING-0.444
- APICAL_SURFACE-0.378
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.364
- COMPLEMENT-0.358
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HB03GSHF | medulloblastoma | — | 0.963 |
| 2 | BS_9NZ2D6AD | medulloblastoma | — | 0.959 |
| 3 | BS_HE57E1RP | medulloblastoma | — | 0.957 |
| 4 | BS_JZRM1S3T | medulloblastoma | — | 0.956 |
| 5 | BS_YETBN0RQ | medulloblastoma | — | 0.953 |
| 6 | BS_AM70R8RG | medulloblastoma | — | 0.949 |
| 7 | BS_W644VEVE | medulloblastoma | — | 0.949 |
| 8 | BS_M84H3KXA | medulloblastoma | — | 0.948 |
| 9 | BS_TZVFR600 | medulloblastoma | — | 0.945 |
| 10 | BS_7C40TRCY | medulloblastoma | — | 0.944 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.644 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.619 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.619 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.586 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.332 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.317 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.271 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.207 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.163 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.045 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.039 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.008 | Inavolisib | — uncovered |